<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02156895</url>
  </required_header>
  <id_info>
    <org_study_id>A4061075</org_study_id>
    <nct_id>NCT02156895</nct_id>
  </id_info>
  <brief_title>Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea</brief_title>
  <official_title>Post Marketing Surveillance Study To Observe Safety And Efficacy Of Inlyta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to monitor the usage of INLYTA® in real practice, including
      the adverse events associated with INLYTA®.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators can choose any patient who is within the scope of I/E criteria
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2018</start_date>
  <completion_date type="Anticipated">April 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 20, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>bimonthly up to 24 months</time_frame>
    <description>The clinical nature, incidence, duration, and severity of adverse events; discontinuation due to adverse events; outcome and possible causality will be monitored in this study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>bimonthly up to 24 months</time_frame>
    <description>Tumor response based on RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>bimonthly up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>bimonthly up to 24 months</time_frame>
    <description>Progression free survival (PFS) within limited follow up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR)</measure>
    <time_frame>bimonthly up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Advanced Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Patients who are using Axitinib</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axitinib</intervention_name>
    <description>based on Axitinib approval</description>
    <arm_group_label>Patients who are using Axitinib</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Korea who has a disease for which Axitinib is indicated
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed as advanced RCC after failure of one prior systemic therapy.

        Exclusion Criteria:

          -  Any patient who does not agree that Pfizer or companies working on behalf of Pfizer
             can use his/her information.

          -  Patients with hypersensitivity to axitinib or to any other component of INLYTA® .

          -  Patients under 18.

          -  Pregnant women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4061075&amp;StudyName=Post%20Marketing%20Surveillance%20Study%20to%20Observe%20Safety%20and%20Efficacy%20of%20Inlyta%20in%20South%20Korea</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4061075&amp;StudyName=Post+Marketing+Surveillance+Study+To+Observe+Safety+And+Efficacy+Of+Inlyta</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2014</study_first_submitted>
  <study_first_submitted_qc>June 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2014</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Korean PMS of Axitinib</keyword>
  <keyword>Metastatic RCC ; 2nd line only</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

